In the B16 melanoma model system, it has been shown that targeting intratumoral Tregs, using CTLA-4 antibodies, offers tumor protection when combined with CD8 T-cell inducing vaccination (23, 24). The gene discussed is CTLA4; the disease is neoplasm.